Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.07 Billion EUR | 99.06% |
| 2022 | 2.55 Billion EUR | 15.03% |
| 2021 | 2.21 Billion EUR | 39.8% |
| 2020 | 1.58 Billion EUR | 146.8% |
| 2019 | 642.79 Million EUR | 22.07% |
| 2018 | 526.58 Million EUR | 0.41% |
| 2017 | 524.45 Million EUR | 21.32% |
| 2016 | 432.29 Million EUR | 3.19% |
| 2015 | 418.91 Million EUR | 13.76% |
| 2014 | 368.24 Million EUR | -5.43% |
| 2013 | 389.38 Million EUR | 8.42% |
| 2012 | 359.14 Million EUR | 10.49% |
| 2011 | 325.03 Million EUR | 11.59% |
| 2010 | 291.26 Million EUR | 6.05% |
| 2009 | 274.65 Million EUR | -2.15% |
| 2008 | 280.69 Million EUR | 0.98% |
| 2007 | 277.96 Million EUR | 33.37% |
| 2006 | 208.4 Million EUR | -2.69% |
| 2005 | 214.17 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 4.05 Billion EUR | -2.07% |
| 2024 Q1 | 4.57 Billion EUR | -9.96% |
| 2024 Q2 | 4.14 Billion EUR | -9.36% |
| 2023 Q1 | 2.64 Billion EUR | 3.57% |
| 2023 Q2 | 2.58 Billion EUR | -2.19% |
| 2023 Q3 | 5.33 Billion EUR | 106.24% |
| 2023 Q4 | 5.07 Billion EUR | -4.72% |
| 2023 FY | 5.07 Billion EUR | 99.06% |
| 2022 Q1 | 2.15 Billion EUR | -2.65% |
| 2022 FY | 2.55 Billion EUR | 15.03% |
| 2022 Q2 | 2.24 Billion EUR | 4.1% |
| 2022 Q3 | 2.74 Billion EUR | 22.24% |
| 2022 Q4 | 2.55 Billion EUR | -7.15% |
| 2021 Q3 | 2.21 Billion EUR | 20.99% |
| 2021 Q4 | 2.21 Billion EUR | 0.23% |
| 2021 FY | 2.21 Billion EUR | 39.8% |
| 2021 Q1 | 1.75 Billion EUR | 10.74% |
| 2021 Q2 | 1.82 Billion EUR | 4.1% |
| 2020 Q2 | 936.2 Million EUR | 44.14% |
| 2020 Q1 | 649.5 Million EUR | 1.04% |
| 2020 FY | 1.58 Billion EUR | 146.8% |
| 2020 Q4 | 1.58 Billion EUR | 61.24% |
| 2020 Q3 | 983.9 Million EUR | 5.1% |
| 2019 Q4 | 642.79 Million EUR | 8.0% |
| 2019 FY | 642.79 Million EUR | 22.07% |
| 2019 Q2 | 586.6 Million EUR | -2.99% |
| 2019 Q3 | 595.2 Million EUR | 1.47% |
| 2019 Q1 | 604.7 Million EUR | 14.83% |
| 2018 Q3 | 609.4 Million EUR | 5.05% |
| 2018 Q1 | 541.8 Million EUR | 3.31% |
| 2018 Q4 | 526.58 Million EUR | -13.59% |
| 2018 FY | 526.58 Million EUR | 0.41% |
| 2018 Q2 | 580.1 Million EUR | 7.07% |
| 2017 Q4 | 524.45 Million EUR | -0.48% |
| 2017 FY | 524.45 Million EUR | 21.32% |
| 2017 Q1 | 497.4 Million EUR | 15.06% |
| 2017 Q2 | 538.2 Million EUR | 8.2% |
| 2017 Q3 | 527 Million EUR | -2.08% |
| 2016 FY | 432.29 Million EUR | 3.19% |
| 2016 Q3 | 469.5 Million EUR | 0.62% |
| 2016 Q2 | 466.6 Million EUR | 8.56% |
| 2016 Q1 | 429.8 Million EUR | 2.6% |
| 2016 Q4 | 432.29 Million EUR | -7.92% |
| 2015 Q4 | 418.91 Million EUR | -2.55% |
| 2015 Q3 | 429.9 Million EUR | 0.8% |
| 2015 Q2 | 426.5 Million EUR | 7.54% |
| 2015 Q1 | 396.6 Million EUR | 7.7% |
| 2015 FY | 418.91 Million EUR | 13.76% |
| 2014 FY | 368.24 Million EUR | -5.43% |
| 2014 Q4 | 368.24 Million EUR | -10.36% |
| 2014 Q3 | 410.8 Million EUR | -1.15% |
| 2014 Q2 | 415.6 Million EUR | 3.05% |
| 2014 Q1 | 403.3 Million EUR | 2.99% |
| 2013 FY | 389.38 Million EUR | 8.42% |
| 2013 Q4 | 391.57 Million EUR | 14.66% |
| 2013 Q2 | 362.4 Million EUR | 0.0% |
| 2013 Q3 | 341.5 Million EUR | -5.77% |
| 2012 FY | 359.14 Million EUR | 10.49% |
| 2012 Q2 | 356.1 Million EUR | 0.0% |
| 2011 Q2 | 316.8 Million EUR | 0.0% |
| 2011 FY | 325.03 Million EUR | 11.59% |
| 2010 Q2 | 300.5 Million EUR | 0.0% |
| 2010 FY | 291.26 Million EUR | 6.05% |
| 2009 FY | 274.65 Million EUR | -2.15% |
| 2009 Q4 | 274.65 Million EUR | 0.0% |
| 2008 FY | 280.69 Million EUR | 0.98% |
| 2007 FY | 277.96 Million EUR | 33.37% |
| 2006 FY | 208.4 Million EUR | -2.69% |
| 2005 FY | 214.17 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.34 Million USD | -216016.474% |
| Ansell Limited | 1.32 Billion USD | -281.862% |
| Ansell Limited | 1.33 Billion USD | -281.147% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 126.33 Million USD | -3919.701% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 943.17 Thousand USD | -538338.376% |
| Psykey, Inc. | 2.47 Million USD | -205169.24% |
| ConvaTec Group Plc | 2.01 Billion USD | -151.637% |
| ConvaTec Group Plc | 2.02 Billion USD | -151.282% |
| Encision Inc. | 1.98 Million USD | -255871.871% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 3.04 Million USD | -166926.314% |
| Innovative MedTech Inc. | 6.13 Million USD | -82679.625% |
| LifePoint, Inc. | 2.45 Million USD | -206829.515% |
| Medite Cancer Diagnostics, Inc. | 10.18 Million USD | -49781.151% |
| Paradigm Medical Industries, Inc. | 3.4 Million USD | -149264.706% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 3.04 Million USD | -166934.884% |
| Reflect Scientific, Inc. | 776.32 Thousand USD | -654055.648% |
| SmileDirectClub, Inc. | 982.26 Million USD | -417.011% |
| Sector 10, Inc. | 9.84 Million USD | -51481.303% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.35 Billion USD | -274.594% |
| SheerVision, Inc. | 1.43 Million USD | -354684.781% |
| United Health Products, Inc. | 1.99 Million USD | -253963.673% |
| Vasamed, Inc. | 1 Million USD | -505062.638% |
| Wearable Health Solutions, Inc. | 3.8 Million USD | -133532.083% |
| Yubo International Biotech Limited | 2.91 Million USD | -174180.455% |